Nemolizumab for Eczema

"At the time of writing, 14 different medical centres are recruiting participants for this trial. Troy, Beaumont and New york have clinics involved but there are also other spots throughout the United States that may be closer to you- it is wise to pick a location near your home in order to reduce any travel strain associated with taking part."

"The medical trial is open to 70 youths aged 2-12 suffering from dermatitis. The main criteria for eligibility include: an area of affected skin larger than 10% Body Surface Area (BSA) at both screening and baseline, a Peak Pruritus Numerical Rating Score of 4 or higher during the two visits, daily application of moisturizer as prescribed by their doctor with authorization to use topical corticosteroids if determined appropriate; compliance with all time requirements and procedural provisions specified in the clinical trial protocol, Eczema Area Severity Index score 16+ at both assessment points and Investigator Global Assessment score 3+ on those same occasions"

"Affirmative. Documents hosted on clinicaltrials.gov show that this medical research, posted on June 24th 2021, is actively in search of volunteers. 70 prospective participants must be sourced from 14 distinct locations."

"The requirements for joining this medical trial dictate that participants must be aged between 2 to 12. There are 106 trials involving individuals under 18 years old, and 173 studies recruiting patients over the age of 65."

"Nemolizumab's research has taken place since 2019, when the first Galderma R&D-sponsored trial was conducted with 750 participants. Its Phase 3 approval came shortly after and now there are 9 concurrent studies occurring in 228 cities across 25 nations."

"At present, 9 clinical trials are assessing the efficacy of nemolizumab with 6 of those in phase 3. Primarily centered around Regensburg, Missouri, this medication is being tested at an impressive 959 different sites throughout the world."

"According to our team at Power, nemolizumab is believed to be relatively safe as there exists some data backing up its safety profile despite the lack of evidence for efficacy. This assessment resulted in a score of 2 on our 1-3 scale."

"Indeed, clinicaltrials.gov indicates that active recruitment for this trial is taking place. It was posted on June 24th 2021 and last updated on July 20th 2022, with 70 participants required from 14 different locations."